Oxbryta
FDA approves GBT’s Oxbryta to treat sickle cell disease
November 26, 2019Manufacturing and Production FDA, FDA Trump, Oxbryta, Sickle cell, sickle cell disease
The FDA announced yesterday that it has approved Global Blood Therapeutics’ marketing application for its haemoglobin polymerisation inhibitor Oxbryta, which …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
